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Abstract  
Objectives: Recent years have brought a shift 
towards evidence-based fracture risk engines.  Fracture 
Risk Assessment Tool (FRAX®) is one such diagnostic 
tool used to evaluate the ten-year probability 
of osteoporotic fracture risk. The aim of this study was 
to evaluate the Maltese FRAX® score-based osteoporosis 
management guidelines and identify the suitability of 
using such a risk factor engine-based protocol. 
Study design: Data from 702 patients presenting 
for bone mineral density (BMD) estimation in 2010-
2011 were collected. In this period, local guidelines 
were devised but not yet put into practice so all referred 
patients underwent BMD estimation. These patients 
were below 65 years of age and above the minimum age 
for FRAX® use: 40 years. Data included Age, Weight, 
Height, BMI and the presence of any risk factor 
components of the FRAX® score tool. BMD was 
assessed using Norland/Hologic densitometers. FRAX® 
scores (excluding BMD) for each patient were calculated 
using the online tool www.shef.ac.uk/FRAX as accessed 
in 2014. The resulting major osteoporotic fracture risk 
was compared to age-specific assessment thresholds as 
set by Kanis et al. (2013). Thus the appropriateness (or 
otherwise) of densitometry measurements as dictated by 
local guidelines was determined.  
Main outcome measures: The main outcome 
measures in this study were the femoral neck and 
vertebral body BMD. The sensitivity, specificity, 
positive predictive value (PPV) and negative predictive 
value (NPV) of using the FRAX®-based guidelines in 
under 65 year olds were calculated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results: Local guidelines for managing <65 
year olds were found to have a PPV of 11.26% and a 
NPV of 94.38 % 
Conclusion: FRAX®-guided local guidelines are 
well suited at excluding non-osteoporotic patients (False 
omission rate of 5.62 %). Positive likelihood ratio for the 
protocol was found to be 1.27. This means that 1 in 
every 8.8 patients that would have been referred for 
BMD estimation were actually osteoporotic. 
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Introduction 
Due to increased longevity modern societies in 
developed countries face the exponential challenge of 
ageing populations. Consequently certain chronic 
medical conditions are becoming more frequent thus 
increasing the morbidity and mortality of the patients 
concerned. These chronic conditions are also consuming 
a bigger component of our health budgets.1 
One of the problems associated with the aging 
process is a decrease in bone mass resulting in 
osteoporosis.2 Osteoporosis has been defined as a multi-
factorial skeletal condition which is characterised by low 
bone mass and a deterioration of bone tissue leading to a 
deterioration of its macro and micro-architecture.3 This 
results in increased bone fragility and consequently 
increased risk of fractures. It is termed to be a “silent 
disease”, however, osteoporosis has potential serious 
implications on the functional status of the individuals 
concerned as well as the national health economy.4 
The diagnosis of osteoporosis is dependent on the 
presence of either a fragility fracture or else on the bone 
density measurement. These fragility fractures can occur 
at any anatomical site although certain sites have been 
considered to be more characteristic than others. 
Vertebral fractures are the most common and even so, a 
significant proportion are clinically undiagnosed.5 Hip 
fractures are associated with significant morbidity and 
mortality. About 50% of patients who lived 
independently before sustaining a hip fracture are unable 
regain their independent lifestyle.6 
The World Health Organization (WHO) developed 
Bone Mineral Density (BMD) criteria for the diagnosis 
of osteoporosis from epidemiologic data that describe 
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the normal distribution of BMD in a young healthy 
reference population.7-8 Osteoporosis is diagnosed when 
the BMD at the spine, hip, or wrist is 2.5 or more 
standard deviations (SD) below the reference mean. Low 
bone density or mass (sometimes referred to as 
osteopenia) is diagnosed when BMD is between 1.0–2.5 
SD below the reference mean. 
The number of standard deviation units above or 
below the young healthy mean is called the T-score. 
Another score used in the interpretation of BMD results 
is the Z-score which signifies the number of standard 
deviation units above or below the mean for the 
individual’s own age group. Unfortunately BMD is only 
assessing one aspect of this condition and it does not 
cater for other factors such as bone quality and 
architecture which may play a significant role in fracture 
prediction.9 
The epidemiology, pathophysiology and treatment 
of osteoporosis have greatly improved in the past decade 
and a change has been noted, from subjective case-
specific strategies to risk engines that integrate all the 
risk factors, country-specific fracture rates and health-
economic scenarios to offer country-specific 
intervention thresholds. 
Various tools have been proposed so as to assess 
the patient’s fracture risk by incorporating clinical risk 
factors with BMD.  The World Health Organisation has 
developed one such tool which is based on individual 
patient models and incorporates the risks associated with 
clinical risk factors as well as BMD at the femoral neck. 
This tool is known as Fracture Risk Assessment Tool 
(FRAX®) and was developed at the World Health 
Organization Collaborating Centre for Metabolic Bone 
Diseases, in the University of Sheffield, UK.10 
The algorithms used in FRAX® provide the 10-year 
probability of patients sustaining a fracture. The results 
are given as the 10-year probability of a fracture at the 
hip as well as at other sites such as spine, forearm, or 
shoulder (major osteoporotic fractures). The 10-year 
fracture probability is calculated from age, body mass 
index and dichotomized risk factors comprising prior 
fragility fracture (a fracture caused by injury that would 
be insufficient to fracture a normal bone), current 
tobacco smoking, use of long-term oral glucocorticoids, 
rheumatoid arthritis, other causes of secondary 
osteoporosis and alcohol consumption.  
The FRAX tool has been adopted at the Bone 
Density unit in Mater Dei Hospital in Malta. According 
to Maltese National Osteoporosis Management 
Guidelines women over 65 years of age with a FRAX® 
score (including BMD) above the intervention threshold 
are referred to the appropriate specialist for treatment. If 
FRAX® score (including BMD) lies below the 
intervention threshold, then the patient is re-assessed 
after two years. (Figure 1) Women under the age of 65 
years who have a 10-year fracture probability as 
obtained using FRAX® (excluding BMD) above the 
assessment threshold limits described below (Table 1) 
are referred for BMD assessment. If FRAX® (excluding 
BMD) 10-year fracture risk lies below the threshold the 
patient is reassured and reassesed after two years. 
(Figure 2) All patients with a history of previous 
fragility fracture are investigated and treated.  The aim 
of this study was to assess the reliability of these 
guidelines and identify any particular positive or 
negative aspects of using such a risk factor engine-based 
protocol. 
 
Table 1: Age-specific major osteoporotic fracture risk 
assessment thresholds as used in  FRAX-score guided 
local guidelines 
 
Age 
10-year Fracture 
probability (%) 
40 – 44 2.3 
45 - 49 2.4 
50 – 54 2.9 
54 - 59 3.6 
60 - 64 4.9 
 
Methods 
Data for 702 patients that presented for official 
radiographic investigation of bone mineral density 
(BMD) estimation in 2010-2011 were collected. The 
data were collected during a period when local 
guidelines on management of osteoporosis were devised 
but not yet put into practice. Consequently, all referred 
patients underwent BMD estimation. It included age, 
indication for the test, weight, height and current 
medication. The presence of any of the risk factor 
components in the FRAX® score tool was also noted: 
previous fragility fracture, family history of hip fracture, 
tobacco use, alcohol consumption, glucocorticoid use,  
secondary causes of osteoporosis and confirmed 
rheumatoid arhritis. BMD (Lumbar and Femoral T-
score) was assessed using Norland or Hologic 
densitometers and was noted on patients’ data sheets. 
BMI was calculated following data entry.  
FRAX® scores (without including BMD) for each 
patient were calculated using the online tool 
www.shef.ac.uk/FRAX® as accessed between July-
October 2014. The resulting major osteoporotic fracture 
risk was compared to age-specific risk thresholds as set 
by Kanis et al. (2013). Thus the appropriateness (or 
otherwise) of densitometry measurements as dictated by 
local guidelines was determined. 
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Figure 1: Maltese Osteoporosis Management guidelines concerning over 65 year olds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Maltese Osteoporosis Management guidelines concerning 40-64 year olds 
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Results 
 
Patient Data 
Table 2: Mean BMI, probability of major osteoporotic risk and hip fracture risk in the studied population 
 
Table of Sensitivity and Specificity 
Table 3: Sensitivity and specificity of using the local osteoporosis management guidelines according to age group 
FRAX®(without BMD) based guideline use for managing under 65 year olds was found to have a positive predictive 
value of 11.26% (CI 8.45% to 14.62%)  and a negative predictive value of 94.38% (CI 90.90% to 96.82%) 
 
Sensitivity, specificity, positive predictive 
value and negative predictive value of using the 
FRAX® engine in under 65 year olds were 
calculated using true positive/negative and false 
positive/negative rates of each age group as 
described in local Maltese guidelines. The age 
groups under investigation were: 40-44, 45-49, 50-
54, 55-59 and 60-64 year olds.  
 
Discussion 
From the data obtained it can be observed that 
FRAX®-guided local guidelines are well suited at 
excluding patients who are not osteoporotic. This can be 
seen from the high negative predictive value of 94.32% 
(with a false ommission rate of only 5.68%). If FRAX-
guided local guidelines were strictly adhered to during 
this period, 252 bone density measurements (35.9% of 
all estimations) could have been avoided.  
The likelihood ratios are used as part of evidence-
based medicine to assess the value of carrying out a 
diagnostic test, in this case using the FRAX® score. The 
positive likelihood ratio for the protocol was found to be 
1.27. This means that 1 in every 8.8 patients that would 
have been referred for BMD estimation would have 
actually been osteoporotic.  
The protocol has a mean sensitivity of 76.56% 
across age groups, with the highest sensitivity being in 
the older age groups. This means that in these patients 
there is a higher probability that osteoporotics are 
correctly identified. The sensitivity of the local protocol 
investigated in this study is comparable to that obtained 
by Henry and colleagues in 2011.11 This study 
prospectively evaluated the use of FRAX® in the United 
Kingdom (Sensitivity of 64.2%, Specificity of 62.9%) 
and in the United States (Sensitivity of 66.7%, 
Specificity of 59.7%). In a population of 
postmenopausal Thai women, Yingyuenyong and 
colleagues found FRAX® to have a sensitivity of 83.6% 
and a specificity of 72.1%.12 The specificity of the 
protocol in the Maltese population (39.21%) is lower 
than that quoted in these studies. These observations 
may be due to dissimilarities in the assessment 
thresholds used, wherein increasing the sensitivity of a 
protocol (by lowering assessment thresholds) comes at 
the expense of decreasing the protocol’s specificity. In 
this regard, a study by Bansal et al (2015) found 
lowering the assessment threshold from >9.3% major 
osteoporotic fracture risk (as recommended by the US 
preventative Services Task Force) to 5.5% resulted in a 
higher sensitivity (From 37 to 80%) and a lower 
specificity (From 74 to 27%).13 
In agreement with other studies, linear regression 
analysis of Hip and Vertebral T-scores found them to be 
 
AGE GROUP 
 
POPULATION 
SIZE (N) 
 
MEAN BMI 
MEAN 10 YEAR PROBABILITY OF 
MAJOR OSTEOPOROTIC 
FRACTURE (FRAX) 
MEAN 10 YEAR 
PROBABILITY OF HIP 
FRACTURE (FRAX) 
40-44 5 26.4 2.28 0.2 
45-49 40 27.7 2.82 0.255 
50-54 184 28.1 3.29 0.38 
55-59 226 27.9 4.62 0.74 
60-64 247 28.6 6.78 1.45 
AGE GROUP 40-44 45-49 50-54 55-59 60-64 OVERALL 
TRUE POSITIVE 0 1 4 18 26 49 
FALSE POSITIVE 1 27 83 124 151 386 
TRUE NEGATIVE 4 11 92 79 66 252 
FALSE NEGATIVE 0 1 5 5 4 15 
SENSITIVITY 0% 50% 44.44% 78.26% 86.67% 76.56% 
95% CI:64.3-86.2% 
SPECIFICITY 80% 28.95% 52.57% 38.92% 30.41% 39.21% 
95% CI:35.7-43.41% 
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in a significant negative relationship with age and in a 
positive relationship with BMI. This could be suggestive 
of a protective effect of obesity on bone density. In 
obese postmenopausal women, increased estrogen 
synthesis by fat tissue has been suggested as one of the 
potential mechanisms for the protective effect of fat 
mass on bone.14 
A follow up assessment of the Maltese National 
Osteoporosis Management guidelines is planned in the 
coming years to assess the impact they will have on 
local practice and cost-effectiveness of bone mineral 
density estimation and to evaluate how these can be 
improved. A ten year follow up of the patients involved 
in this study is also planned in order to assess actual 
fracture incidence. 
 
Conclusion  
FRAX®-guided local guidelines are well suited at 
excluding non-osteoporotic patients, with a false 
omission rate of 5.62%. The sensitivity of the local 
protocol increases with increasing age, and its proper use 
in the Maltese community care could reduce load at the 
Bone Density units at Mater Dei Hospital.  
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